PURPOSE: Numerous examples from animal models and clinical trials showed that HER-2-derived peptides are naturally processed as a CTL epitope and can be recognized by tumor-specific CTLs in several tumors with HER-2 overexpression. The humanized anti-HER-2 monoclonal antibody, Herceptin, has been designed to specifically antagonize the HER-2 function by directing against the extracellular domain of the HER-2 protein. One of the actions of Herceptin includes the internalization and degradation of HER-2, which might increase the amount of HER-2-derived peptides available for loading to MHC class I. EXPERIMENTAL DESIGN: In the present study, we investigated how Herceptin treatment of HER-2-overexpressing targets affects lysis by HER-2-specific CTLs. RESULTS: We showed that Herceptin sensitized HER-2-overexpressing tumors to lysis by HLA-A2-restricted or HLA-A24-restricted CTLs, without any effect of the expression of MHC class I, costimulatory molecules, adhesion molecules, or TAP-1 on the targets. Furthermore, the enhancement of cytolytic activity with Herceptin was inhibited by addition of a specific proteasome inhibitor, lactacystin. CONCLUSIONS: These results suggested that Herceptin treatment might enhance the class I-restricted presentation of endogenous HER-2 antigen via the proteasome step, resulting in higher susceptibility of HER-2-overexpressing tumors to lysis by the HER-2-specific CTLs.
PURPOSE: Numerous examples from animal models and clinical trials showed that HER-2-derived peptides are naturally processed as a CTL epitope and can be recognized by tumor-specific CTLs in several tumors with HER-2 overexpression. The humanized anti-HER-2 monoclonal antibody, Herceptin, has been designed to specifically antagonize the HER-2 function by directing against the extracellular domain of the HER-2 protein. One of the actions of Herceptin includes the internalization and degradation of HER-2, which might increase the amount of HER-2-derived peptides available for loading to MHC class I. EXPERIMENTAL DESIGN: In the present study, we investigated how Herceptin treatment of HER-2-overexpressing targets affects lysis by HER-2-specific CTLs. RESULTS: We showed that Herceptin sensitized HER-2-overexpressing tumors to lysis by HLA-A2-restricted or HLA-A24-restricted CTLs, without any effect of the expression of MHC class I, costimulatory molecules, adhesion molecules, or TAP-1 on the targets. Furthermore, the enhancement of cytolytic activity with Herceptin was inhibited by addition of a specific proteasome inhibitor, lactacystin. CONCLUSIONS: These results suggested that Herceptin treatment might enhance the class I-restricted presentation of endogenous HER-2 antigen via the proteasome step, resulting in higher susceptibility of HER-2-overexpressing tumors to lysis by the HER-2-specific CTLs.
Authors: T Maruyama; K Mimura; E Sato; M Watanabe; Y Mizukami; Y Kawaguchi; T Ando; H Kinouchi; H Fujii; K Kono Journal: Br J Cancer Date: 2010-07-13 Impact factor: 7.640
Authors: Paula J Whittington; Marie P Piechocki; Henry H Heng; Jennifer B Jacob; Richard F Jones; Jessica B Back; Wei-Zen Wei Journal: Cancer Res Date: 2008-09-15 Impact factor: 12.701
Authors: Bharat K R Chaganty; Yang Lu; Songbo Qiu; Srinivas S Somanchi; Dean A Lee; Zhen Fan Journal: Oncoimmunology Date: 2015-10-29 Impact factor: 8.110
Authors: John Stagg; Janelle Sharkey; Sandra Pommey; Richard Young; Kazuyoshi Takeda; Hideo Yagita; Ricky W Johnstone; Mark J Smyth Journal: Proc Natl Acad Sci U S A Date: 2008-10-06 Impact factor: 11.205